DSpace Repository

Novel antibodies directed against the human erythropoietin receptor: Creating a basis for clinical implementation

Show simple item record

dc.contributor.author Maxwell, P.
dc.contributor.author Melendez-Rodríguez, F.
dc.contributor.author Matchett, K.B.
dc.contributor.author Aragones, J.
dc.contributor.author Ben-Califa, N.
dc.contributor.author Jaekel, H.
dc.contributor.author Hengst, L.
dc.contributor.author Lindner, H.
dc.contributor.author Bernardini, A.
dc.contributor.author Brockmeier, U.
dc.contributor.author Fandrey, J.
dc.contributor.author Grunert, F.
dc.contributor.author Oster, H.S.
dc.contributor.author Mittelman, M.
dc.contributor.author El-Tanani, M.
dc.contributor.author Thiersch, M.
dc.contributor.author Schneider Gasser, E.M.
dc.contributor.author Gassmann, M.
dc.contributor.author Dangoor, D.
dc.contributor.author Cuthbert, R.J.
dc.contributor.author Irvine, A.
dc.contributor.author Jordan, A.
dc.contributor.author Lappin, T.
dc.contributor.author Thompson, J.
dc.contributor.author Neumann, D.
dc.date.accessioned 2019-02-22T14:54:59Z
dc.date.available 2019-02-22T14:54:59Z
dc.date.issued 2014
dc.identifier.uri http://doi.org/10.1111/bjh.13133
dc.identifier.uri http://repositorio.upch.edu.pe/handle/upch/5685
dc.description.abstract Recombinant human erythropoietin (rHuEPO) is an effective treatment for anaemia but concerns that it causes disease progression in cancer patients by activation of EPO receptors (EPOR) in tumour tissue have been controversial and have restricted its clinical use. Initial clinical studies were flawed because they used polyclonal antibodies, later shown to lack specificity for EPOR. Moreover, multiple isoforms of EPOR caused by differential splicing have been reported in cancer cell lines at the mRNA level but investigations of these variants and their potential impact on tumour progression, have been hampered by lack of suitable antibodies. The EpoCan consortium seeks to promote improved pathological testing of EPOR, leading to safer clinical use of rHuEPO, by producing well characterized EPOR antibodies. Using novel genetic and traditional peptide immunization protocols, we have produced mouse and rat monoclonal antibodies, and show that several of these specifically recognize EPOR by Western blot, immunoprecipitation, immunofluorescence, flow cytometry and immunohistochemistry in cell lines and clinical material. Widespread availability of these antibodies should enable the research community to gain a better understanding of the role of EPOR in cancer, and eventually to distinguish patients who can be treated safely by rHuEPO from those at increased risk from treatment.
dc.language.iso eng
dc.publisher Wiley
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans
dc.subject Animals
dc.subject anemia
dc.subject Risk Assessment
dc.subject Risk assessment
dc.subject human
dc.subject Amino Acid Sequence
dc.subject Article
dc.subject immunoreactivity
dc.subject risk assessment
dc.subject Mice
dc.subject immunology
dc.subject immunohistochemistry
dc.subject erythropoietin receptor
dc.subject genetics
dc.subject metabolism
dc.subject animal tissue
dc.subject nonhuman
dc.subject rat
dc.subject animal
dc.subject mouse
dc.subject Rats
dc.subject Fluorescent Antibody Technique
dc.subject Molecular Sequence Data
dc.subject Flow Cytometry
dc.subject procedures
dc.subject animal cell
dc.subject signal transduction
dc.subject human tissue
dc.subject Western blotting
dc.subject cancer patient
dc.subject recombinant erythropoietin
dc.subject immune response
dc.subject protein domain
dc.subject biosynthesis
dc.subject bone marrow biopsy
dc.subject molecular genetics
dc.subject messenger RNA
dc.subject human cell
dc.subject flow cytometry
dc.subject monoclonal antibody
dc.subject mass spectrometry
dc.subject gene silencing
dc.subject pleiotropy
dc.subject amino acid sequence
dc.subject Receptors, Erythropoietin
dc.subject Antibodies, Monoclonal
dc.subject fluorescent antibody technique
dc.subject immunofluorescence
dc.subject cancer growth
dc.subject high performance liquid chromatography
dc.subject Janus kinase 2
dc.subject nomenclature
dc.subject Terminology as Topic
dc.subject synthesis
dc.subject cancer cell line
dc.subject drug megadose
dc.subject Erythropoietin receptor
dc.subject Antibody
dc.subject Cancer anaemia
dc.subject cancer immunization
dc.subject Chemistry Techniques, Synthetic
dc.subject fluorescence activated cell sorting
dc.subject Gene Silencing
dc.subject genetic immunization
dc.subject glycophorin C
dc.subject immunoprecipitation
dc.subject Immunoprecipitation
dc.subject Neoplasm Proteins
dc.subject receptor binding
dc.subject Recombinant erythropoietin
dc.subject STAT5 protein
dc.subject tumor cell culture
dc.subject Tumor Cells, Cultured
dc.subject tumor growth
dc.subject tumor protein
dc.title Novel antibodies directed against the human erythropoietin receptor: Creating a basis for clinical implementation
dc.type info:eu-repo/semantics/article
dc.identifier.journal British Journal of Haematology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account